Deal Theory: a Biopharma Deal Maker’s Approach to Maximizing Strategic Partnerships
Deal Theory In the summer of 2019, Locust Walk launched a blog post, Financing overhang or hangover: The impact on partnerships […]
Deal Theory In the summer of 2019, Locust Walk launched a blog post, Financing overhang or hangover: The impact on partnerships […]
Deal Makers of Japan Locust Walk has been active in Asia, in particular, Japan for nearly half of the firm’s
2019 Year End Biopharma Report Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and
2019 Medtech Year End Review Report Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions
Q3 2019 Report: Global Trends in Medtech Transactions Locust Walk is a global life science transaction firm. Our integrated team-based
Q3 2019 Report: Global Trends in Biopharma Transactions Locust Walk is a global life science transaction firm. Our integrated team-based
Whitepaper Download: Inside Out Inside Out: Do Recent Acquisitions by “Big Pharma” Sound the Alarm for the Traditional R&D Model?
CATEGORIES News Events Publications ARCHIVE Chris Ehrlich of Locust Walk to speak at Dartmouth Entrepreneurs Forum On September 6, 2019, Chris
My National Lampoon’s European Vacation CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Market Trends Multitrack
The impact on partnerships for public biotech companies CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends